Biotech News

PepGen Announces Positive Phase 2 FREEDOM2-DM1 10 mg/kg Results Demonstrating Highest Reported Splicing Correction and Improvements Across Multiple Functional Measures

PepGen (PEPG)PepGenClinical readout

- Mean splicing correction of 46.5% following four monthly doses of PGN-EDODM1, five of six participants having more than 20% splicing correction and four participants exceeding 50% splicing correction – - Video Hand Opening Time (vHOT), a measure of myotonia, improved by 3.9 seconds (52.7%) from

Related news

PepGen

Oligonucleotide Delivery Company PepGen develops Enhanced Delivery Oligonucleotides intended to transport therapeutic oligonucleotides into skeletal muscle. PGN-EDODM1 PGN-EDODM1 is designed to correct RNA splicing in myotonic dystrophy type 1 by releasing pathogenic RNA and restoring downstream protein expression. FREEDOM2 The FREEDOM2...

Recent company news

Stock data

Close
3.93 USD
Market cap
100.3M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States